KRAS and non-small cell lung carcinoma: [15–18] Additionally, KRAS subtype-specific inhibitors are being developed.[19] Thus, KRAS mutation subtyping in PDAC patients has the potential to guide precision oncology strategies in the near future, similar to the way KRAS mutations have emerged as predictors of therapy response in non-small cell lung carcinoma and colon cancer patients.